```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssptamxg1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11   KOREAPAT updates resume
 NEWS  6  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  8  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 10  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 11  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14   FSTA enhanced with Japanese patents
 NEWS 14  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11   CA/CAplus enhanced with more pre-1907 records
 NEWS 19  SEP 21   CA/CAplus fields enhanced with simultaneous left and right
                   truncation
 NEWS 20  SEP 25   CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS 21  SEP 25   CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 22  SEP 25   CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 23  SEP 28   CEABA-VTB classification code fields reloaded with new
                   classification scheme

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *
```

```
FILE 'HOME' ENTERED AT 06:48:26 ON 02 OCT 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.63       0.63

FILE 'REGISTRY' ENTERED AT 06:50:03 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 SEP 2006  HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES:  29 SEP 2006  HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s GTS-21
          3377 GTS
        380751 21
L1           2 GTS-21
                 (GTS(W)21)

=> d

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   221029-72-7  REGISTRY
ED   Entered STN:  08 Apr 1999
CN   Phenol, 4-[(E)-(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-
     methoxy- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   4-OH-GTS 21
FS   STEREOSEARCH
MF   C18 H18 N2 O2
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER

Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    11.86      12.49

FILE 'CAPLUS' ENTERED AT 06:50:16 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Oct 2006  VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006  (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1 and sepsis
            81 L1
         14391 SEPSIS
L2           0 L1 AND SEPSIS

=> s l1 and (peritonitis or panceatitis or sepsis or ischemia)
            81 L1
          3519 PERITONITIS
             2 PANCEATITIS
         14391 SEPSIS
         70051 ISCHEMIA
L3           8 L1 AND (PERITONITIS OR PANCEATITIS OR SEPSIS OR ISCHEMIA)

=> d 1-8 bib abs hitstr
```

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1311413 CAPLUS
DN 144:45474
TI Method of treating and preventing arthritis, cutaneous and cardiovascular inflammatory-related diseases using nicotinic receptor agonists
IN Cormier, Yvon; Israel-Assayag, Evelyne
PA Asmacure Ltee, Can.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005117860	A1	20051215	WO 2005-CA872	20050603

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-576292P P 20040603

AB The present invention relates to a composition comprising a nicotinic receptor agonist and method for preventing and treating inflammatory diseases related to body inflammation including arthritis, cutaneous inflammation and cardio-vascular inflammatory related diseases. Particular nicotinic receptor agonists disclosed for the treatment and prevention of arthritis, cutaneous inflamation and cardiovascular inflamatory related diseases include dimethylphenylpiperazinium (DMPP), nicotine, epibatidine, cytisine, mecamylamine, acetylcholine, pyridyl ethers, tubocurarine, trimethaphan, hexamethonium, N-methylcaramylcholine, ABT-418, GTS-21, MLA, DHβE, Arecoline, lobeline, philanthotoxin-433, azabicyclin, SIB-1553, and imidacloprit.

IT 156223-05-1, Gts-21
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating and preventing arthritis, cutaneous and cardiovascular inflammatory-related diseases using nicotinic receptor agonists)

RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



2 HCl

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1036892 CAPLUS
DN 142:735
TI Compositions for the treatment of reduced blood flow
IN Stephenson, Diane T.; Taylor, Duncan P.; Arneric, Stephen P.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103357	A1	20041202	WO 2004-US14988	20040513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2525280	AA	20041202	CA 2004-2525280	20040513
	US 2005113433	A1	20050526	US 2004-845009	20040513
	EP 1628650	A1	20060301	EP 2004-785541	20040513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004010287	A	20060516	BR 2004-10287	20040513
PRAI	US 2003-470278P	P	20030514		
	WO 2004-US14988	W	20040513		

OS MARPAT 142:735
AB The present invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cholinergic agent

in combination with a Ph acetic acid cyclooxygenase-2 selective inhibitor.

IT 156223-05-1, GTS 21 156223-05-1D, GTS 21, isomers, esters, or prodrugs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of reduced blood flow)

RN 156223-05-1 CAPLUS

CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 156223-05-1 CAPLUS

CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1036850 CAPLUS
DN 142:16839
TI Compositions of a chromene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
IN Stephenson, Diane T.; Taylor, Duncan P.; Arneric, Stephen P.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103300	A2	20041202	WO 2004-US15278	20040513
	WO 2004103300	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005101629	A1	20050512	US 2004-845012	20040513
PRAI	US 2003-470351P	P	20030514		

OS MARPAT 142:16839
AB The invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cholinergic agent in combination with a chromene cyclooxygenase-2 selective inhibitor.
IT 156223-05-1, GTS 21 156223-05-1D, GTS 21, esters, isomers, and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chromene cyclooxygenase-2 selective inhibitor-cholinergic agent combination for treatment of reduced blood flow or trauma to CNS)
RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1033559 CAPLUS
DN 141:420469
TI Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
IN Stephenson, Diane T.; Taylor, Duncan P.; Arneric, Stephen P.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103286	A2	20041202	WO 2004-US14987	20040513
	WO 2004103286	A3	20060202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005026919	A1	20050203	US 2004-844921	20040513
PRAI	US 2003-470352P	P	20030514		

OS MARPAT 141:420469

AB The invention provides compns. and methods for the treatment of reduced blood flow to the central nervous system or traumatic injury to the central nervous system in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or traumatic injury comprising the administration to a subject of a cholinergic agent in combination with a cyclooxygenase-2 selective inhibitor.

IT 156223-05-1, GTS 21 156223-05-1D, GTS 21, isomers, salts, and esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitor-cholinergic agent combination for treatment of reduced blood flow or trauma to CNS)

RN 156223-05-1 CAPLUS

CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



O_2 HCl

RN 156223-05-1 CAPLUS

CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



2 HCl

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1033557 CAPLUS
DN 142:732
TI Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
IN Stephenson, Diane T.; Taylor, Duncan P.; Arneric, Stephen P.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103284	A2	20041202	WO 2004-US14984	20040513
	WO 2004103284	A3	20051110		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2525571	AA	20041202	CA 2004-2525571	20040513
	US 2005159471	A1	20050721	US 2004-845574	20040513
	EP 1628653	A2	20060301	EP 2004-752099	20040513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010305	A	20060523	BR 2004-10305	20040513
PRAI	US 2003-470373P	P	20030514		
	WO 2004-US14984	W	20040513		

OS MARPAT 142:732
AB The invention provides methods and compns. for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cholinergic agent in

combination with a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor.

IT 156223-05-1, GTS 21 156223-05-1D, GTS 21, isomers, salts, and esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzenesulfonamide derivative or methylsulfonylbenzene derivative COX2 inhibitor-cholinergic agent combination for treatment of reduced blood flow or trauma to CNS)

RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:166608 CAPLUS
DN 130:223475
TI synthesis, methods of use and compns. for benzylidene- and cinnamylidene-anabaseines for use in nicotine addiction and neuropathological disorders
IN Meyer, Edwin; Kem, William R.; Van Haaren, Frans; Zoltewicz, John A.; Defiebre, Christopher M.; Papke, Roger; Day, Arthur L.
PA University of Florida, USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9910338	A2	19990304	WO 1998-US17850	19980828
	WO 9910338	A3	19990514		
	W: JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5977144	A	19991102	US 1997-924008	19970829
	EP 1045842	A2	20001025	EP 1998-944579	19980828
	EP 1045842	B1	20030514		
	R: DE, FR, GB, IT, NL				
	JP 2003524575	T2	20030819	JP 2000-507667	19980828
PRAI	US 1997-924008	A	19970829		
	US 1992-938427	B2	19920831		
	US 1995-392763	A2	19950223		
	WO 1998-US17850	W	19980828		

OS MARPAT 130:223475
GI



I

AB Synthesis of benzylidene- and cinnamylidene-anabaseines (I), compns. and methods for using these compns. for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors are described. Thus, I (X = =CHCH=CH, R1, R2, R3, R4 = H) (II) is prepared by condensation of trans-cinnamaldehyde with anabaseine dihydrochloride in 68% yield. II shows a value of 94.7 in α7 receptor binding oocyte assay. I target the alpha7 receptor subtype with little or no activation of the alpha4beta2 or other receptor subtypes.

IT 221029-72-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, methods of use and compns. for benzylidene- and cinnamylidene-anabaseines for use in nicotine addiction and neuropath.

disorders)
RN 221029-72-7 CAPLUS
CN Phenol, 4-[(E)-(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:19159 CAPLUS
DN 130:205039
TI GTS-21, a nicotinic agonist, attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats
AU Nanri, Masato; Miyake, Hidekazu; Murakami, Yukihisa; Matsumoto, Kinzo; Watanabe, Hiroshi
CS Section of Pharmacology Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, 771-0132, Japan
SO Japanese Journal of Pharmacology (1998), 78(4), 463-469
CODEN: JJPAAZ; ISSN: 0021-5198
PB Japanese Pharmacological Society
DT Journal
LA English
AB The authors examined the effects of GTS-21 [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride], a nicotinic agonist, on histopathol. changes of the brain and radial maze learning performance in rats with permanent occlusion of the bilateral common carotid arteries (2VO) and elucidated whether this compound has a protective effect against the neuronal degeneration and spatial cognitive deficit caused by chronic ischemia. Rats were administered GTS-21 (1 and 10 mg/kg, p.o.) or vehicle 24 h and 30 min before the 2VO operation and then once daily for 2 mo after the operation. The 2VO rats given vehicle had multiple infarctions in the cerebral cortex, hippocampus and striatum and rarefaction in the white matter at 2 mo after the operation, although the number and distribution of infarctions varied among individual animals. In addition, the 2VO rats given vehicle showed a higher rate of errors in the acquisition trials of the 8-arm radial maze task than sham-operated controls. However, 2VO rats treated with GTS-21 (1 and 10 mg/kg, p.o.) showed significantly decreased neuropathol. changes and less errors in the acquisition trials compared to the vehicle-treated 2VO rats. These results indicate that GTS-21 attenuates impairment of spatial cognitive deficit and progressive neuronal degeneration induced by 2VO and suggest that this compound is beneficial for the treatment of neurodegenerative diseases following chronic cerebral hypoperfusion.
IT 156223-05-1, GTS-21
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic agonist GTS-21 attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats to induce cerebral ischemia in relation to neuroprotectant effect)

RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:65099 CAPLUS
DN 128:213203
TI Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils
AU Nanri, Masato; Yamamoto, Jyunji; Miyake, Hidekazu; Watanabe, Hiroshi
CS Department of Pharmacology, Taiho Pharmaceutical Co., Ltd., Tokushima, 771-01, Japan
SO Japanese Journal of Pharmacology (1998), 76(1), 23-29
CODEN: JJPAAZ; ISSN: 0021-5198
PB Japanese Pharmacological Society
DT Journal
LA English
AB The neuroprotective effects of GTS-21 were studied and compared with those of (-)-nicotine, 9-amino-1,2,3,4-tetrahydroacridine-HCl (THA) and pentobarbital Na (PB) by using a cerebral ischemia model in Mongolian gerbils. The learning performance and memory retention were elucidated by a step-through passive avoidance task 2 and 3 days after ischemia-reperfusion. In this task, the ischemic gerbils showed impairment of learning performance and memory retention. Neuronal cell death in the hippocampal CA1 area was observed 7 days after ischemia . When administered i.p. 30 min before ischemia, GTS-21 (5 mg/kg), (-)-nicotine (1.5 mg/kg), THA (5 mg/kg) and PB (50 mg/kg) attenuated the impairment of passive avoidance performance and the neuronal cell death induced by the ischemia. When administered orally twice daily for 2 wk prior to the ischemia, GTS-21 (10 mg/kg) suppressed both amnesia and neuronal cell death, while (-)-nicotine (10 mg/kg) and THA (10 mg/kg) suppressed only the amnesia. These results suggest that GTS-21 exerts a protective activity on not only impairment of learning and memory but also delayed neuronal death and that the underlying mechanism of GTS-21 differs from that of nicotine or THA.
IT 156223-05-1, GTS-21
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(delayed hippocampal neuronal death in cerebral ischemia
inhibition by)
RN 156223-05-1 CAPLUS
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l1 and (respiratory or "COPD" or lupus or allograft or asthma or "cystic fibrosis")
81 L1
120075 RESPIRATORY
2784 "COPD"
16734 LUPUS
10811 ALLOGRAFT
32419 ASTHMA
15586 "CYSTIC"
34532 "FIBROSIS"
11800 "CYSTIC FIBROSIS"
("CYSTIC"(W)"FIBROSIS")
L4 0 L1 AND (RESPIRATORY OR "COPD" OR LUPUS OR ALLOGRAFT OR ASTHMA OR "CYSTIC FIBROSIS")

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.80	82.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.00	-6.00

FILE 'REGISTRY' ENTERED AT 06:57:28 ON 02 OCT 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:   29 SEP 2006  HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES:  29 SEP 2006  HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s us 2004-0204355/pn
L5            0 US 2004-0204355/PN
                (US2004204355/PN)

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.20      87.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -6.00

FILE 'REGISTRY' ENTERED AT 06:58:15 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 SEP 2006  HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES:  29 SEP 2006  HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s us 2004-0204355/pn
L6            0 US 2004-0204355/PN
                (US2004204355/PN)

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.20      92.69
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -6.00

FILE 'CAPLUS' ENTERED AT 06:58:20 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Oct 2006  VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006  (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 2004-0204355/pn
L7          1 US 2004-0204355/PN
              (US2004204355/PN)

=> sel rn
E1 THROUGH E39 ASSIGNED

=> file reg
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   2.49      95.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -6.00

FILE 'REGISTRY' ENTERED AT 06:58:31 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 SEP 2006  HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES:  29 SEP 2006  HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
```

on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s 1-39
      19309815 1
         80027 39
L8         552 1-39
               (1(W)39)

=> s l7
L9           0 US 2004-0204355/PN
               (US2004204355/PN)

=> s us 2004-0204355/pn
L10          0 US 2004-0204355/PN
               (US2004204355/PN)

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    19.48     114.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -6.00

FILE 'CAPLUS' ENTERED AT 06:58:55 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Oct 2006  VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006  (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 2004-0204355/pn
L11          1 US 2004-0204355/PN
               (US2004204355/PN)

=> sel rn
E40 THROUGH E78 ASSIGNED

=> file re
'RE' IS AN AMBIGUOUS FILE OR CLUSTER NAME
 REACTION          - Reactions Cluster
 RESEARCH          - Research Cluster
 REGISTRY          - The CAS Registry File of substances
ENTER FILE OR CLUSTER NAME (IGNORE):reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	2.49	117.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.00

FILE 'REGISTRY' ENTERED AT 06:59:09 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l7
L12 0 US 2004-0204355/PN
(US2004204355/PN)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.20	122.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.00

FILE 'CAPLUS' ENTERED AT 06:59:20 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006 (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 2004-0204355/pn
L13 1 US 2004-0204355/PN
(US2004204355/PN)

=> sel rn
E79 THROUGH E117 ASSIGNED

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.49	124.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.00

FILE 'REGISTRY' ENTERED AT 06:59:36 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s e79-117
1 156223-05-1/BI
(156223-05-1/RN)
1 156743-78-1/BI
(156743-78-1/RN)
1 156743-79-2/BI
(156743-79-2/RN)
1 156743-85-0/BI
(156743-85-0/RN)
1 178419-47-1/BI
(178419-47-1/RN)
1 220099-94-5/BI
(220099-94-5/RN)
1 248270-40-8/BI
(248270-40-8/RN)
1 248270-41-9/BI
(248270-41-9/RN)
1 248270-43-1/BI
(248270-43-1/RN)
1 248270-44-2/BI

(248270-44-2/RN)
1 248270-45-3/BI
(248270-45-3/RN)
1 373358-00-0/BI
(373358-00-0/RN)
1 400855-55-2/BI
(400855-55-2/RN)
1 400855-58-5/BI
(400855-58-5/RN)
1 400855-62-1/BI
(400855-62-1/RN)
1 400855-94-9/BI
(400855-94-9/RN)
1 5937-29-1/BI
(5937-29-1/RN)
1 855559-41-0/BI
(855559-41-0/RN)
1 855559-42-1/BI
(855559-42-1/RN)
1 855559-43-2/BI
(855559-43-2/RN)
1 855559-44-3/BI
(855559-44-3/RN)
1 855559-45-4/BI
(855559-45-4/RN)
1 855559-46-5/BI
(855559-46-5/RN)
1 855559-47-6/BI
(855559-47-6/RN)
1 855559-48-7/BI
(855559-48-7/RN)
1 855559-49-8/BI
(855559-49-8/RN)
1 855559-50-1/BI
(855559-50-1/RN)
1 855559-51-2/BI
(855559-51-2/RN)
1 855559-52-3/BI
(855559-52-3/RN)
1 855559-53-4/BI
(855559-53-4/RN)
1 855559-54-5/BI
(855559-54-5/RN)
1 855559-55-6/BI
(855559-55-6/RN)
1 855559-56-7/BI
(855559-56-7/RN)
1 855559-57-8/BI
(855559-57-8/RN)
1 855559-58-9/BI
(855559-58-9/RN)
1 855559-59-0/BI
(855559-59-0/RN)
1 855559-60-3/BI
(855559-60-3/RN)
1 855559-61-4/BI
(855559-61-4/RN)
1 9000-92-4/BI
(9000-92-4/RN)

L14 39 (156223-05-1/BI OR 156743-78-1/BI OR 156743-79-2/BI OR 156743-85-0/BI OR 178419-47-1/BI OR 220099-94-5/BI OR 248270-40-8/BI OR 248270-41-9/BI OR 248270-43-1/BI OR 248270-44-2/BI OR 248270-45-3/BI OR 373358-00-0/BI OR 400855-55-2/BI OR 400855-58-5/BI OR 400855-62-1/BI OR 400855-94-9/BI OR 5937-29-1/BI OR 855559-41-0/BI OR 855559-42-1/BI OR 855559-43-2/BI OR 855559-44-3/BI OR 855559

```
            -45-4/BI OR 855559-46-5/BI OR 855559-47-6/BI OR 855559-48-7/BI
            OR 855559-49-8/BI OR 855559-50-1/BI OR 855559-51-2/BI OR 855559-5
            2-3/BI OR 855559-53-4/BI OR 855559-54-5/BI OR 855559-55-6/BI OR
            855559-56-7/BI OR 855559-57-8/BI OR 855559-58-9/BI OR 855559-59-0
            /BI OR 855559-60-3/BI OR 855559-61-4/BI OR 9000-92-4/BI)

=> d 79-117
     39 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):79-117
     39 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):1-39

L14  ANSWER 1 OF 39  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   855559-61-4  REGISTRY
ED   Entered STN:  17 Jul 2005
CN   DNA, d(C-C-C-C-A-T-G-G-C-C-C-T-G-G-C-A-C-T-G-C) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   21: PN: US20050137218 SEQID: 21 unclaimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14  ANSWER 2 OF 39  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   855559-60-3  REGISTRY
ED   Entered STN:  17 Jul 2005
CN   DNA, d(G-G-G-C-T-C-C-A-T-G-G-G-C-T-A-C-C-G-G-A) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   20: PN: US20050137218 SEQID: 20 unclaimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14  ANSWER 3 OF 39  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   855559-59-0  REGISTRY
ED   Entered STN:  17 Jul 2005
CN   DNA, d(G-C-A-G-C-G-C-A-T-G-T-T-G-A-G-T-C-C-C-G) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   19: PN: US20050137218 SEQID: 19 unclaimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 4 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-58-9 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(G-G-C-T-C-G-A-G-T-C-A-C-C-A-G-T-G-T-G-G-T-T-A-C-G-C-A-A-A-G-T-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 18: PN: US20050137218 SEQID: 18 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 5 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-57-8 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(C-A-A-G-G-A-T-C-C-G-G-A-C-T-C-A-A-C-A-T-G-C-G-C-T-G-C-T-C-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 17: PN: US20050137218 SEQID: 17 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 6 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-56-7 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(G-G-T-A-C-G-G-A-T-G-T-G-C-C-A-A-G-G-A-G-T) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 16: PN: US20050137218 SEQID: 16 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 7 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-55-6 REGISTRY

ED Entered STN: 17 Jul 2005
CN DNA, d(C-G-A-C-A-C-G-G-A-G-A-C-G-T-G-G-A-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 15: PN: US20050137218 SEQID: 15 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 8 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-54-5 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(G-A-C-T-A-C-T-C-A-G-T-G-G-C-C-C-T-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 14: PN: US20050137218 SEQID: 14 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 9 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-53-4 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(A-G-G-T-G-C-C-T-C-T-G-T-G-G-C-C-G-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 13: PN: US20050137218 SEQID: 13 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 10 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-52-3 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(A-T-G-A-C-T-T-T-C-G-C-C-A-C-C-T-T-C-T-T-C-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: US20050137218 SEQID: 12 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 11 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-51-2 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(A-G-A-G-C-C-T-G-T-G-A-A-C-A-C-C-A-A-T-G-T-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: US20050137218 SEQID: 11 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 12 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-50-1 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(T-G-C-A-G-A-T-G-A-T-G-G-T-G-A-A-G-A-C-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 10: PN: US20050137218 SEQID: 10 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 13 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-49-8 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(C-C-C-G-G-C-A-A-G-A-G-G-A-G-T-G-A-A-A-G-G-T) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 9: PN: US20050137218 SEQID: 9 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 14 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-48-7 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(G-T-A-T-G-T-G-G-T-C-C-A-T-C-A-C-C-A-T-T-G-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 8: PN: US20050137218 SEQID: 8 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 15 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-47-6 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(A-T-C-A-C-C-T-A-C-C-A-C-T-T-C-G-T-C-A-T-G-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7: PN: US20050137218 SEQID: 7 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 16 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-46-5 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(T-C-T-G-T-G-A-C-T-A-A-T-C-C-G-C-T-C-T-T-G-C) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: US20050137218 SEQID: 6 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 17 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-45-4 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(C-G-A-G-A-T-C-A-G-T-A-C-G-A-T-G-G-C-C-T-A-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: US20050137218 SEQID: 5 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified

```
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14  ANSWER 18 OF 39  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   855559-44-3  REGISTRY
ED   Entered STN:  17 Jul 2005
CN   DNA, d(A-C-G-A-A-G-T-T-G-G-G-A-G-C-C-G-A-C-A-T-C-A) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   4: PN: US20050137218 SEQID: 4 unclaimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14  ANSWER 19 OF 39  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   855559-43-2  REGISTRY
ED   Entered STN:  17 Jul 2005
CN   DNA, d(G-A-C-T-G-T-T-C-G-T-T-T-C-C-C-A-G-A-T-G-G) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   3: PN: US20050137218 SEQID: 3 unclaimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14  ANSWER 20 OF 39  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   855559-42-1  REGISTRY
ED   Entered STN:  17 Jul 2005
CN   DNA, d(A-A-T-G-A-G-T-C-G-A-C-C-T-G-C-A-A-A-C-A-C-G) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   2: PN: US20050137218 SEQID: 2 unclaimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
```

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 21 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 855559-41-0 REGISTRY
ED Entered STN: 17 Jul 2005
CN DNA, d(C-C-A-G-A-C-C-T-G-A-G-C-A-A-C-T-T-C-A-T-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20050137218 SEQID: 1 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 22 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 400855-94-9 REGISTRY
ED Entered STN: 14 Mar 2002
CN Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[(3-chlorophenyl)thio]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H21 Cl N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 23 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 400855-62-1 REGISTRY
ED Entered STN: 14 Mar 2002
CN Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-(phenylthio)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H22 N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 24 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 400855-58-5 REGISTRY
ED Entered STN: 14 Mar 2002
CN Benzamide, 4-[4-(acetylamino)phenoxy]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H25 N3 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 25 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 400855-55-2 REGISTRY
ED Entered STN: 14 Mar 2002
CN Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-(4-hydroxyphenoxy)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H22 N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 26 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 373358-00-0 REGISTRY
ED Entered STN: 04 Dec 2001
CN Carbamic acid, 1-azabicyclo[2.2.2]oct-3-yl-, 1-(2-fluorophenyl)ethyl ester (9CI) (CA INDEX NAME)
MF C16 H21 F N2 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 27 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 248270-45-3 REGISTRY
ED Entered STN: 22 Nov 1999
CN 2,3'-Bipyridine, 3,4,5,6-tetrahydro-3-[(2E)-3-(4-methoxyphenyl)-2-propenylidene]-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H20 N2 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 28 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 248270-44-2 REGISTRY
ED Entered STN: 22 Nov 1999
CN 2,3'-Bipyridine, 3,4,5,6-tetrahydro-3-[(2E)-3-(2-methoxyphenyl)-2-propenylidene]-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H20 N2 O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 29 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 248270-43-1 REGISTRY
ED Entered STN: 22 Nov 1999
CN 2,3'-Bipyridine, 3,4,5,6-tetrahydro-3-[(2E)-3-phenyl-2-propenylidene]-, (3E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H18 N2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 30 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 248270-41-9 REGISTRY
ED Entered STN: 22 Nov 1999
CN Phenol, 2-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-5-methoxy-
(9CI) (CA INDEX NAME)
MF C18 H18 N2 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 31 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 248270-40-8 REGISTRY
ED Entered STN: 22 Nov 1999
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy-
(9CI) (CA INDEX NAME)
MF C18 H18 N2 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 32 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 220099-94-5 REGISTRY
ED Entered STN: 02 Mar 1999
CN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-phenyl- (9CI) (CA INDEX NAME)
MF C19 H20 N2 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 33 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 178419-47-1 REGISTRY
ED Entered STN: 17 Jul 1996
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, (3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, (-)-
OTHER NAMES:
CN AR-R 17779
FS STEREOSEARCH
MF C9 H14 N2 O2
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

29 REFERENCES IN FILE CA (1907 TO DATE)
29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 34 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 156743-85-0 REGISTRY
ED Entered STN: 03 Aug 1994
CN 2,3'-Bipyridine, 3,4,5,6-tetrahydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)
MF C18 H18 N2 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 35 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 156743-79-2 REGISTRY
ED Entered STN: 03 Aug 1994
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]- (9CI) (CA INDEX NAME)
MF C17 H16 N2 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 36 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN

RN 156743-78-1 REGISTRY
ED Entered STN: 03 Aug 1994
CN Benzenamine, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]- (9CI) (CA INDEX NAME)
MF C17 H17 N3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 37 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 156223-05-1 REGISTRY
ED Entered STN: 08 Jul 1994
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (3E)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,3'-Bipyridine, 3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-, dihydrochloride, (E)-
OTHER NAMES:
CN DMBX-anabaseine
CN DMXB-A
CN GTS 21
FS STEREOSEARCH
MF C19 H20 N2 O2 . 2 Cl H
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (148372-04-7)

Double bond geometry as shown.



●2 HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

77 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
77 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 38 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 9000-92-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Amylase (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Amylolytic enzymes
CN Amylopol P
CN Amylosa enzyme
CN Amzyme 60
CN Amzyme TX 8
CN Aquasim 240L
CN Aquazym Ultra
CN Aquazym Ultra 1200L
CN Bakezyme P 500G
CN Bakezyme P500
CN Biodiastase 1000
CN Biodiastase 1000/2000
CN Biodiastase 2000
CN Biozyme S
CN Dabiase K 27
CN Diastase
CN Diramyl
CN Duramyl
CN Duramyl 300L
CN Duramyl 60T
CN Ecostone A 200
CN Enzylase C
CN Enzyme S 120L
CN Enzyme S 280L
CN Enzymes, amylolytic
CN Fetilase
CN Fungamyl 1600BG
CN Fungamyl Super AX
CN G-zyme 990
CN G-zyme 998

CN Gamalpha G 120
CN Gamylo 200L
CN Glucozyme DB
CN Glycogenase
CN GRINDAMYL Amylase 1000
CN Kleistase M 20
CN Kleistase M 5
CN Kleistase T
CN Kleistase TU 20
CN Kokugen T
CN L 2000
CN L 2000 (enzyme)
CN Lactose RCS
CN Malt diastase
CN Miola
CN Mylase 100
CN Natalase
CN Neospitase K
CN Optimax HP 7525
CN Raktase SuperConc
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 8049-91-0, 9000-93-5, 9014-71-5
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20510 REFERENCES IN FILE CA (1907 TO DATE)
115 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20533 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L14 ANSWER 39 OF 39 REGISTRY COPYRIGHT 2006 ACS on STN
RN 5937-29-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 8-Azoniabicyclo[3.2.1]octane, 3-(benzoyloxy)-2-(methoxycarbonyl)-8,8-dimethyl-, iodide, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1αH,5αH-Tropanium, 2β-carboxy-3β-hydroxy-8-methyl-, iodide, methyl ester, benzoate (8CI)
CN 8-Azoniabicyclo[3.2.1]octane, 3-(benzoyloxy)-2-(methoxycarbonyl)-8,8-dimethyl-, iodide, [1R-(exo,exo)]-
OTHER NAMES:
CN (-)-Cocaine methiodide
CN Cocaine methiodide
FS STEREOSEARCH
MF C18 H24 N O4 . I
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, EMBASE, MEDLINE, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
CRN (133097-15-1)

Absolute stereochemistry.



I⁻

32 REFERENCES IN FILE CA (1907 TO DATE)
32 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 248270-40-8/rn
L15           1 248270-40-8/RN

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    75.86     200.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -6.00

FILE 'CAPLUS' ENTERED AT 07:02:08 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Oct 2006  VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006  (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 248270-40-8/rn
              8 248270-40-8
              0 248270-40-8D
L16           8 248270-40-8/RN
                  (248270-40-8 (NOTL) 248270-40-8D )

=> s l16 and (respiratory or "COPD" or lupus or allograft or asthma or "cystic
fibrosis")
         120075 RESPIRATORY
           2784 "COPD"
          16734 LUPUS
```

```
        10811 ALLOGRAFT
        32419 ASTHMA
        15586 "CYSTIC"
        34532 "FIBROSIS"
        11800 "CYSTIC FIBROSIS"
                ("CYSTIC"(W)"FIBROSIS")
L17         1 L16 AND (RESPIRATORY OR "COPD" OR LUPUS OR ALLOGRAFT OR ASTHMA
              OR "CYSTIC FIBROSIS")

=> d

L17  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:513538  CAPLUS
DN   141:65099
TI   Inhibition of inflammation using α7 nicotinic receptor-binding
     cholinergic agonists
IN   Tracey, Kevin J.; Wang, Hong
PA   North Shore-Long Island Jewish Research Institute, USA
SO   PCT Int. Appl., 75 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004052365        A2    20040624    WO 2003-US38708         20031205
     WO 2004052365        A3    20040923
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2507502           AA    20040624    CA 2003-2507502         20031205
     AU 2003298939        A1    20040630    AU 2003-298939          20031205
     EP 1581223           A2    20051005    EP 2003-796701          20031205
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1735414           A     20060215    CN 2003-80108261        20031205
     JP 2006514946        T2    20060518    JP 2004-559325          20031205
PRAI US 2002-431650P      P     20021206
     WO 2003-US38708      W     20031205
OS   MARPAT 141:65099


=> s l16
             8 248270-40-8
             0 248270-40-8D
L18          8 248270-40-8/RN
                (248270-40-8 (NOTL) 248270-40-8D )

=> d 1-8 bib abs hitstr

L18  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:626208  CAPLUS
DN   145:265053
TI   Spectroscopic Analysis of Benzylidene Anabaseine Complexes with
     Acetylcholine Binding Proteins as Models for Ligand-Nicotinic Receptor
     Interactions
AU   Talley, Todd T.; Yalda, Samar; Ho, Kwok-Yiu; Tor, Yitzhak; Soti, Ferene
     S.; Kem, William R.; Taylor, Palmer
```

CS Department of Pharmacology, University of California, La Jolla, CA, 92093-0636, USA
SO Biochemistry (2006), 45(29), 8894-8902
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
AB The discovery of the acetylcholine binding proteins (AChBPs) has provided critical soluble surrogates for examining structure and ligand interactions with nicotinic receptors and related pentameric ligand-gated ion channels. The multiple marine and freshwater sources of AChBP constitute a protein family with substantial sequence divergence and selectivity in ligand recognition for analyzing structure-activity relationships. The purification of AChBP in substantial quantities in the absence of a detergent enables one to conduct spectroscopic studies of the ligand-AChBP complexes. To this end, we have examined the interaction of a congeneric series of benzylidene-ring substituted anabaseines with AChBPs from Lymnaea, Aplysia, and Bulinus species and correlated their binding energetics with spectroscopic changes associated with ligand binding. The anabaseines display agonist activity on the α7 nicotinic receptor, a homomeric receptor with sequences similar to those of the AChBPs. Substituted anabaseines show absorbance and fluorescence properties sensitive to the protonation state, relative permittivity (dielec. constant), and the polarizability of the surrounding solvent or the proximal residues in the binding site. Absorbance difference spectra reveal that a single protonation state of the ligand binds to AChBP and that the bound ligand experiences a solvent environment with a high degree of polarizability. Changes in the fluorescence quantum yield of the bound ligand reflect the rigidification of the ring system of the bound ligand. Hence, the spectral properties of the bound ligand allow a description of the electronic character of the bound state of the ligand within its aromatic binding pocket and provide information complementary to that of crystal structures in defining the determinants of interaction.
IT 248270-40-8
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(spectroscopic anal. of benzylidene-ring substituted anabaseine complexes with different invertebrate acetylcholine binding proteins as models for ligand-nicotinic receptor interactions)
RN 248270-40-8 CAPLUS
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:523981 CAPLUS
DN 145:117530
TI N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine
AU Zhang, Ran; White, Natalie A.; Soti, Ferenc S.; Kem, William R.; Machu,

Tina K.
CS Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA
SO Journal of Pharmacology and Experimental Therapeutics (2006), 317(3), 1276-1284
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB The present study tested the hypothesis that mouse and human 5-hydroxytryptamine3A (5-HT3A) receptors may be differentially modulated by benzylidene analogs of anabaseine (BA) and that these analogs may be useful in assessing residues involved in receptor gating. Mouse and human wild-type and mouse and human chimeric 5-HT3A receptors expressed in Xenopus oocytes were evaluated with the two-electrode voltage clamp technique. The authors' previous studies demonstrated that 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXBA) is an antagonist at the mouse wild-type 5-HT3A receptor, but that its metabolites 3-(2-hydroxy, 4-methoxybenzylidene)-anabaseine (2-OHMBA), 3-(2-methoxy, 4-hydroxybenzylidene)-anabaseine (4-OHMBA), and 3-(2,4-dihydroxybenzylidene)-anabaseine (2,4-DiOHBA) are partial agonists. In the human wild-type (HWT) 5-HT3A receptor, none of the BA compds. possessed partial agonist activity. BA compds. antagonized 1.5 μM 5-HT-mediated (EC50) responses in the HWT 5-HT3A receptor with a rank order of potency (IC50 in μM) of 2-OHMBA (1.5±0.1) > DMXBA (3.1±0.2) > 4-OHMBA (7.4±0.5) > 2,4-DiOHBA (12.8±0.7). In mouse receptor chimeras containing N-terminal human receptor orthologs, 2-OHMBA inhibited 5-HT-mediated (EC50) currents with IC50 values of 2.0±0.08 and 3.0±0.13 μM, resp. In human receptor chimeras containing N-terminal mouse receptor orthologs, 2-OHMBA displayed partial agonist activities with EC50 values of 1.3±0.15 and 5.0±0.4 μM; efficacies were 43 and 57%, resp. Thus, amino acids present in the distal one-third of the N terminus of mouse and human 5-HT3A receptors are necessary and sufficient to confer partial agonist or antagonist properties of 2-OHMBA.
IT 248270-40-8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-terminal domains in mouse and human 5-hydroxytryptamine3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine)
RN 248270-40-8 CAPLUS
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:13528 CAPLUS
DN 144:101040
TI Method of treating ileus by pharmacological activation of cholinergic receptors
IN Tracey, Kevin J.; Fink, Mitchell P.
PA North Shore-Long Island Jewish Research Institute, USA
SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006002375	A2	20060105	WO 2005-US22495	20050623
WO 2006002375	A3	20060629		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-582545P P 20040623
OS MARPAT 144:101040
AB A method of treating ileus in a subject by administering to the subject an effective amount of a pharmacol. agent that increases the activity of cholinergic receptor in a subject is described. Examples of pharmacol. agents are brain muscarinic agonist, cholinergic agonist or cholinesterase inhibitor. The methods of the present invention can be used to treat ileus caused by abdominal surgery, or administration of narcotics or chemotherapeutic agents such as during cancer chemotherapy.
IT 248270-40-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activation of cholinergic receptors by muscarinic agonist, cholinergic agonist or cholinesterase inhibitor for treatment of ileus)
RN 248270-40-8 CAPLUS
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1354908 CAPLUS
DN 144:64357
TI Controlling angiogenesis with anabaseine analogs
IN Kem, William R.
PA University of Florida Research Foundation, Inc., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005123075	A2	20051229	WO 2005-US19942	20050608
WO 2005123075	A3	20060223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005288333 A1 20051229 US 2005-147996 20050608

PRAI US 2004-577990P P 20040608

OS MARPAT 144:64357

AB Compds. controlling angiogenesis and vasculogenesis. In particular, induction of angiogenesis to promote growth of new vasculature by the use of anabaseine agonists and to the reduction of pathol. angiogenesis by the use of anabaseine antagonists. For example, 3-(2,4-dimethoxy)benzylidene anabaseine (DMXBA) synthesized by reacting anabaseine dihydrochloride with 2,4-dimethoxybenzaldehyde was found to be an agonist of α4β2 nicotinic receptor.

IT 248270-40-8P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesized anabaseine analogs for controlling angiogenesis in wound healing and tumor growth and other diseases)

RN 248270-40-8 CAPLUS

CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:547267 CAPLUS

DN 143:71763

TI Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists

IN Tracey, Kevin J.; Wang, Hong

PA North Shore Long-Island Jewish Research Institute, USA

SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 729,427.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005137218	A1	20050623	US 2004-957426	20040930
	US 2004204355	A1	20041014	US 2003-729427	20031205
PRAI	US 2002-431650P	P	20021206		
	US 2003-729427	A2	20031205		

AB A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that

is released from a macrophage wherein said condition is acute pancreatitis. The compds. of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-Et ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulas (I), (II), (III) and (IV) are described herein.

IT 248270-40-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of pancreatitis using α7 receptor-binding cholinergic agonists)

RN 248270-40-8 CAPLUS

CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:547081 CAPLUS

DN 141:117380

TI The structural basis for GTS-21 selectivity between human and rat nicotinic α7 receptors

AU Stokes, Clare; Papke, Julia Kay Porter; Horenstein, Nicole A.; Kem, William R.; McCormack, Thomas J.; Papke, Roger L.

CS Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, FL, USA

SO Molecular Pharmacology (2004), 66(1), 14-24
CODEN: MOPMA3; ISSN: 0026-895X

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB The α7 nAChR-selective partial agonist 3-(2,4-dimethoxybenzylidene)anabasine (GTS-21) is more efficacious and potent for rat receptors than for human α7 receptors. Four single amino acid differences exist between human and rat α7 in the agonist binding site, two in the C loop, and one each in the E and F loops. Reciprocal mutations were made in these three domains and evaluated in Xenopus laevis oocytes. Mutations in the C and F loops significantly increased the efficacy of GTS-21 for the human receptor mutants but not to the level of the wild-type, and reciprocal mutations in rat α7 did not decrease responses to GTS-21. Whereas mutations in the E loop alone were without effect, the E- and F-loop mutations together increased GTS-21 efficacy and potency for human receptors, but the EF mutations in the rat receptors decreased the GTS-21 potency without changing the efficacy. The only mutants that showed a full reversal of the efficacy differences between human and rat α7 contained complete exchange of all four sites in the C, E, and F loops or just the sites in the C and F loops. However, the reversal of the potency ratio seen with the EF mutants was not evident in the CEF mutants. Our data therefore indicate that the pharmacol. differences between rat and human α7 receptors are caused by reciprocal differences in sites within and around the binding site.

Specific features in the agonist mol. itself are also identified that interact with these structural features of the receptor agonist binding site.

IT 248270-40-8
RL: BSU (Biological study, unclassified); BIOL (Biological study) (structural basis for selectivity of GTS-21 and anabaseine compds. between human and rat nicotinic α7 receptors)

RN 248270-40-8 CAPLUS
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:513538 CAPLUS
DN 141:65099
TI Inhibition of inflammation using α7 nicotinic receptor-binding cholinergic agonists
IN Tracey, Kevin J.; Wang, Hong
PA North Shore-Long Island Jewish Research Institute, USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052365	A2	20040624	WO 2003-US38708	20031205
	WO 2004052365	A3	20040923		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507502	AA	20040624	CA 2003-2507502	20031205
	AU 2003298939	A1	20040630	AU 2003-298939	20031205
	EP 1581223	A2	20051005	EP 2003-796701	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1735414	A	20060215	CN 2003-80108261	20031205
	JP 2006514946	T2	20060518	JP 2004-559325	20031205
PRAI	US 2002-431650P	P	20021206		
	WO 2003-US38708	W	20031205		

OS MARPAT 141:65099
AB Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein

the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an α7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell. Addnl., methods for determining whether a compound is a cholinergic antagonist reactive with an α7 nicotinic receptor are provided. These methods comprise determining whether the compound reduces the ability of a cholinergic agonist to inhibit the release of a proinflammatory cytokine from a mammalian cell. Oligonucleotides or mimetics capable of inhibiting attenuation of lipopolysaccharide-induced TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are also provided. The oligonucleotides or mimetics consist essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 receptor. Addnl., methods of inhibiting attenuation of TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are provided. These methods comprise treating the macrophage with the above-described oligonucleotide or mimetic. Sepsis in mice was treated with 3-(2,4-dimethoxybenzylidene)anabaseine.

IT 248270-40-8
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as cholinergic agonist of α7 nicotinic receptor; inflammation inhibition with α7 nicotinic receptor-binding cholinergic agonists)

RN 248270-40-8 CAPLUS
CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:704996 CAPLUS
DN 131:317796
TI Methods of use and compositions for nicotinic α7 receptor-targeting benzylidene- and cinnamylidene-anabaseines, and preparation thereof
IN Meyer, Edwin; Kem, William; Van haaren, Franz; Zoltewicz, John A.; De Fiebre, Christopher M.; Papke, Roger; Day, Arthur
PA University of Florida, USA
SO U.S., 42 pp., Cont.-in-part of U.S. 5,741,802.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5977144	A	19991102	US 1997-924008	19970829
	WO 9910338	A2	19990304	WO 1998-US17850	19980828
	WO 9910338	A3	19990514		
	W: JP				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

	EP 1045842	A2	20001025	EP 1998-944579	19980828
	EP 1045842	B1	20030514		
	R: DE, FR, GB, IT, NL				
	JP 2003524575	T2	20030819	JP 2000-507667	19980828
PRAI	US 1992-938427	B2	19920831		
	US 1995-392763	A2	19950223		
	US 1997-924008	A	19970829		
	WO 1998-US17850	W	19980828		

OS MARPAT 131:317796

AB Benzylidene- and cinnamylidene-anabaseine compns., and methods using these compns. for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors, are provided. The compns. target the α7 receptor subtype with little or no activation of the α4β2 or other receptor subtypes.

IT 248270-40-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinic α7 receptor-targeting benzylidene- and cinnamylidene-anabaseine preparation and therapeutic use)

RN 248270-40-8 CAPLUS

CN Phenol, 4-[(5,6-dihydro[2,3'-bipyridin]-3(4H)-ylidene)methyl]-3-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.69	267.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.00	-12.00

FILE 'CAPLUS' ENTERED AT 07:06:08 ON 02 OCT 2006

```
FILE COVERS 1907 - 2 Oct 2006  VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006  (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l14
L19      20673 L14

=> s l19 and peritonitis or pancreatitis or sepsis or respiratory or "COPD" or
allograft or athma or fibrosis)
UNMATCHED RIGHT PARENTHESIS 'FIBROSIS)'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l19 and(peritonitis or pancreatitis or sepsis or respiratory or "COPD" or
allograft or athma or fibrosis)
          3519 PERITONITIS
          8871 PANCREATITIS
         14391 SEPSIS
        120075 RESPIRATORY
          2784 "COPD"
         10811 ALLOGRAFT
             0 ATHMA
         34532 FIBROSIS
L20       1215 L19 AND(PERITONITIS OR PANCREATITIS OR SEPSIS OR RESPIRATORY OR
               "COPD" OR ALLOGRAFT OR ATHMA OR FIBROSIS)

=> s l19 and (peritonitis or pancreatitis or sepsis or respiratory or "COPD" or
allograft or athma or fibrosis)
          3519 PERITONITIS
          8871 PANCREATITIS
         14391 SEPSIS
        120075 RESPIRATORY
          2784 "COPD"
         10811 ALLOGRAFT
             0 ATHMA
         34532 FIBROSIS
L21       1215 L19 AND (PERITONITIS OR PANCREATITIS OR SEPSIS OR RESPIRATORY
               OR "COPD" OR ALLOGRAFT OR ATHMA OR FIBROSIS)

=> s l21 and anabaseine
           129 ANABASEINE
L22          1 L21 AND ANABASEINE

=> d

L22  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:513538  CAPLUS
DN   141:65099
TI   Inhibition of inflammation using α7 nicotinic receptor-binding
     cholinergic agonists
IN   Tracey, Kevin J.; Wang, Hong
PA   North Shore-Long Island Jewish Research Institute, USA
SO   PCT Int. Appl., 75 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2004052365        A2    20040624    WO 2003-US38708         20031205
```

```
     WO 2004052365         A3     20040923
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2507502            AA     20040624    CA 2003-2507502         20031205
     AU 2003298939         A1     20040630    AU 2003-298939          20031205
     EP 1581223            A2     20051005    EP 2003-796701          20031205
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1735414            A      20060215    CN 2003-80108261        20031205
     JP 2006514946         T2     20060518    JP 2004-559325          20031205
PRAI US 2002-431650P       P      20021206
     WO 2003-US38708       W      20031205
OS   MARPAT 141:65099


=> d his

     (FILE 'HOME' ENTERED AT 06:48:26 ON 02 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 06:50:03 ON 02 OCT 2006
L1             2 S GTS-21

     FILE 'CAPLUS' ENTERED AT 06:50:16 ON 02 OCT 2006
L2             0 S L1 AND SEPSIS
L3             8 S L1 AND (PERITONITIS OR PANCEATITIS OR SEPSIS OR ISCHEMIA)
L4             0 S L1 AND (RESPIRATORY OR "COPD" OR LUPUS OR ALLOGRAFT OR ASTHMA

     FILE 'REGISTRY' ENTERED AT 06:57:28 ON 02 OCT 2006
L5             0 S US 2004-0204355/PN

     FILE 'REGISTRY' ENTERED AT 06:58:15 ON 02 OCT 2006
L6             0 S US 2004-0204355/PN

     FILE 'CAPLUS' ENTERED AT 06:58:20 ON 02 OCT 2006
L7             1 S US 2004-0204355/PN
               SEL RN

     FILE 'REGISTRY' ENTERED AT 06:58:31 ON 02 OCT 2006
L8           552 S 1-39
L9             0 S L7
L10            0 S US 2004-0204355/PN

     FILE 'CAPLUS' ENTERED AT 06:58:55 ON 02 OCT 2006
L11            1 S US 2004-0204355/PN
               SEL RN

     FILE 'REGISTRY' ENTERED AT 06:59:09 ON 02 OCT 2006
L12            0 S L7

     FILE 'CAPLUS' ENTERED AT 06:59:20 ON 02 OCT 2006
L13            1 S US 2004-0204355/PN
               SEL RN

     FILE 'REGISTRY' ENTERED AT 06:59:36 ON 02 OCT 2006
L14           39 S E79-117
L15            1 S 248270-40-8/RN
```

```
     FILE 'CAPLUS' ENTERED AT 07:02:08 ON 02 OCT 2006
L16             8 S 248270-40-8/RN
L17             1 S L16 AND (RESPIRATORY OR "COPD" OR LUPUS OR ALLOGRAFT OR ASTHM
L18             8 S L16

     FILE 'CAPLUS' ENTERED AT 07:06:08 ON 02 OCT 2006
L19         20673 S L14
L20          1215 S L19 AND(PERITONITIS OR PANCREATITIS OR SEPSIS OR RESPIRATORY
L21          1215 S L19 AND (PERITONITIS OR PANCREATITIS OR SEPSIS OR RESPIRATORY
L22             1 S L21 AND ANABASEINE

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    36.59     303.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -12.00

STN INTERNATIONAL LOGOFF AT 07:09:10 ON 02 OCT 2006
```